Soleno Therapeutics, Inc. (NASDAQ:SLNO) is highlighted as an unstoppable stock by hedge funds, with a new drug, VYKAT XR, approved for Prader-Willi syndrome.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
TD Cowen Starts Coverage Soleno Therapeutics (SLNO) Stock, Gives Buy
